No Vaccine in Sight
The U.S. government contributed research to a Gilead remdesivir patent — but didn’t get credit
Covid Seen as Tipping Point to Lower Drug Prices, Patent Sharing
Coronavirus puts Big Pharma’s IP regime to the test
Coronavirus crisis may bring out old tool in disease fights: suspension of drug patents
Covid-19: Gilead withdraws orphan drug designation from potential treatment after criticism
In rare move, Gilead gives up ‘orphan’ status for experimental coronavirus drug
Ford School hosts conversation on drug patent system reform
Ten years ago, I testified before Congress about drug pricing — and it’s only gotten worse. Here’s what’s wrong, and how we may be able to fix it.
After a pharma lobbying blitz, Congress softens legislation on drug patents